OncRef

Clinical Trial: NCT05635708

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:BeiGene
Information Provided By:BeOne Medicines
Last Update Posted:2026-10-30

Study Overview

Brief Summary

The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (< 50%).

Official Title

Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

Conditions

Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer

Intervention / Treatment

  • Drug: Tislelizumab
  • Drug: BGB-A445
  • Drug: LBL-007
  • Drug: Carboplatin
  • Drug: Cisplatin
  • Drug: pemetrexed
  • Drug: Paclitaxel
  • Drug: Nab paclitaxel
  • Drug: BGB-15025

Other Study ID Numbers

  • BGB-LC-201
  • CTR20230892
  • 2022-502738-18-00

Start Date (Actual)

2023-02-10

Primary Completion Date (Actual)

2025-12-19

Study Completion Date (Actual)

2026-10-29

Enrollment (Actual)

418

Study Type

Interventional

Phase

Phase 2